Skip to main content
Fig. 3 | European Journal of Medical Research

Fig. 3

From: Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19

Fig. 3

Significantly lower SARS-CoV-2 viral protein-specific antibody levels and significantly longer disease duration in individuals carrying the CCR5 delta 32 mutation heterozygously with WHO° 1 and WHO° 2a disease following SARS-CoV-2 infection. SARS-CoV-2 viral protein-specific antibody levels were determined as described in the legend of Fig. 1 in 23 individuals carrying the CCR5 delta 32 mutation heterozygously and in 105 individuals carrying the wild type CCR5 gene (A). Disease duration in individuals with WHO° 1 and WHO° 2a disease following SARS-CoV-2 infection is shown in B for 8 heterozygous carriers of the CCR5 delta mutation and 39 non carriers

Back to article page